Ultragenyx Pharmaceutical Inc is among the 13 Best Revenue Growth Stocks to Buy Right Now. They resubmitted a Biologics License Application for UX111 AAV9 gene therapy to treat Sanfilippo syndrome type A. The FDA has concerns, but approval could make UX111 the first therapy for this type of syndrome. Morgan Stanley analyst maintained a Buy rating on Ultragenyx Pharmaceutical with a price target of $50. Leerink Partners gave a Buy rating, while Wedbush reiterated a Hold rating on the stock. Ultragenyx Pharmaceutical Inc focuses on developing therapies for rare genetic diseases, with products like Crysvita, Mepsevii, Dojolvi, and Evkeeza.

Read more at Yahoo Finance: Ultragenyx Pharmaceutical (RARE) Resubmits Biologics License Application for Gene Therapy Treatment